PepLabo Download

Wegovy® (injection) and nausea

Nausea is the reaction reported most often with Wegovy® injection, in adults and in teenagers. This page stays with that one medicine: the three US trial pools, the EU and Canadian product information, what pooled trial analyses and safety databases add, why the queasiness may happen, what else can cause it, what the manufacturer suggests asking about, and which signs mean you should not wait. The tablets have their own data and their own page.

Published · Updated · Wegovy®: side effects by symptom · Written by the PepLabo editorial team

Nausea in the US, EU and Canadian documents

The US label does not give one nausea figure. Section 6.1 reports injection safety from three separate groups of trials. Table 3 pools three placebo-controlled studies in adults who used 2.4 mg for up to 68 weeks (2,116 on the medicine, 1,261 on placebo; about one in five had type 2 diabetes). Table 4 comes from two 72-week studies of the 7.2 mg strength, in which adults were randomly given 7.2 mg, 2.4 mg or placebo. Table 5 covers a 68-week trial in adolescents aged 12 and older. [1]

The EU and Canadian documents add their own pools and a fact the US tables leave out: how long the episodes lasted. Read the placebo column carefully, because in every pool a sizeable share of people felt queasy with no active medicine at all.

Nausea with Wegovy® injection in official product information (checked 20-10-2026)
Source and trial poolPlaceboWegovy® 2.4 mgWegovy® 7.2 mg
US label, Table 3: adults, up to 68 weeks [1]16%44%not in this pool
US label, Table 4: adults, 72 weeks [1]13%35%39%
US label, Table 5: ages 12 and older, 68 weeks [1]18%42%not studied
EU SmPC section 4.8: STEP 1–4, 68 weeks [2]16.1%43.9% (“very common”); median bout 8 dayslisted only for other reactions
Canadian monograph, Table 4: STEP 1–3 [3]16%44%; median bout 8 daysnot in this monograph

When it shows up, how long it lasts, who stopped

All three documents place digestive reactions mainly in the dose-escalation period. [1][2][3] Section 2.2 of the US label sets out the injection steps: 0.25 mg in weeks 1 to 4, then 0.5 mg, 1 mg and 1.7 mg for four weeks each, and a maintenance dose from week 17. Moving to 7.2 mg is described only for adults who have tolerated 2.4 mg for at least four weeks. If two or more weekly doses in a row are missed, section 2.4 says to restart the climb at a lower dose, again to reduce stomach reactions. [1] Each of these is a decision for your prescriber.

On duration, the EU product information and the Canadian monograph agree: most stomach and bowel events were mild to moderate and short, and the median length of a nausea episode was 8 days, against 2 days for vomiting and 3 for diarrhoea. [2][3] A median is the middle value, so some bouts were shorter and some longer.

In the adult 2.4 mg pool, 6.8% of people on Wegovy® and 3.2% on placebo stopped for good because of an adverse reaction, and nausea was the single most common reason (1.8% versus 0.2%). In the 7.2 mg studies, digestive reactions led 3% of each Wegovy® group and 0.3% of the placebo group to stop. Among teenagers, 2.3% on the medicine and 1.5% on placebo stopped because of a digestive reaction. [1]

What trial analyses and safety databases add

A manufacturer-funded analysis pooled the STEP 1–3 trials (2,117 people on semaglutide 2.4 mg, 1,262 on placebo). Almost all digestive events were non-serious (99.5%) and mild to moderate (98.1%), they were mostly temporary, and they clustered during or shortly after dose escalation. Average weight loss was similar in people who did and did not have such events, and a statistical analysis attributed less than one percentage point of the extra weight loss to them. In STEP 4, people who had already tolerated 20 weeks of the medicine continued the maintenance dose without new tolerability problems. [5]

A study of the US FDA reporting database (FAERS) for 2018 to 2022 looked at 5,442 reports of digestive problems linked to semaglutide. The median time to onset was between 6 and 23 days depending on the signal, and the pattern suggested risk fell over time. [6] Reports of this kind are sent in voluntarily, cannot give a rate and do not prove that the medicine caused the problem; they are useful mainly for timing patterns.

Why semaglutide can make you queasy

  • What the label supports: semaglutide slows stomach emptying (US section 12.2), stomach reactions concentrate around dose increases, and climbing in steps is the label’s own way of lowering that risk. [1]
  • Where the documents differ: the EU product information says no clinically relevant slowing of stomach emptying was seen at 2.4 mg, probably because the body adapts, while the effect of 7.2 mg on emptying was not studied. [2] Across GLP-1 medicines, a meta-analysis of scintigraphy studies measured an average delay of about 36 minutes in the time for half a meal to leave the stomach. [7] Neither source says how much of anyone’s nausea this explains.
  • Proposed, not measured: the EU document notes that the GLP-1 receptor is found in brain areas that regulate appetite and that semaglutide acts there. [2] Whether the same pathways produce the queasy feeling in a given person has not been shown in the product information.
  • General background, not specific to Wegovy®: MedlinePlus lists glutide-type medicines among many everyday causes of nausea, alongside stomach infections and reflux. [8]

Other possible reasons for nausea

Feeling sick while on Wegovy® is not always caused by Wegovy®. MedlinePlus lists stomach or bowel infections, food poisoning, reflux, migraine, pregnancy, motion sickness, severe pain such as kidney stones, heavy cannabis use and slow stomach emptying (gastroparesis), and warns that nausea can also be an early sign of appendicitis, a bowel blockage or an ulcer. [8] Some of these overlap with label warnings: the US label notes appendicitis in 0.5% of adults on Wegovy® versus 0.2% on placebo, and says Wegovy® is not recommended in severe gastroparesis. [1]

Pregnancy deserves its own mention. The Medication Guide asks you to tell your provider if you are pregnant or planning to be, and to stop Wegovy® two months before a planned pregnancy. [1] A new pregnancy is one reason new nausea is worth raising rather than assuming it is the medicine.

What the manufacturer and general guidance describe

Novo Nordisk’s patient page frames its suggestions as things your prescriber may recommend: bland, low-fat foods such as crackers, toast and rice; foods that contain water, such as soup and gelatin; eating more slowly; getting fresh air; and avoiding greasy food and lying down after eating. It also lists questions to ask, for example whether smaller, more frequent meals would help or how to stay hydrated without feeling too full. [4]

MedlinePlus adds that once the cause is known, sipping small amounts of clear liquids often is part of home care. [8] Anti-sickness medicines, ginger products and other remedies are not covered by the Wegovy® label; the Medication Guide asks you to tell your provider about every prescription and over-the-counter medicine, vitamin and herbal supplement you take, because Wegovy® slows stomach emptying and can affect some medicines. [1] Check with your pharmacist or prescriber before adding anything.

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help

SignWho to contactHow fastSource
Stomach pain that is severe and persistent, sometimes spreading to the back, whether or not you also feel sick or vomitStop Wegovy® and call your provider right away; emergency care if severeEmergencyMedication Guide [1]
Blood or coffee-ground-looking material in vomitEmergency number or emergency roomEmergencyMedlinePlus [8]
Severe nausea or vomiting after injecting more than prescribedYour provider, Poison Help (US 1-800-222-1222) or the nearest emergency roomEmergencyMedication Guide [1]
Nausea with vomiting or diarrhoea that does not go away, or signs of dehydration such as little or dark urineYour prescriber, the same dayTodayMedication Guide [1]; MedlinePlus [9]
Pain in the upper stomach with fever, yellow skin or eyes, or clay-coloured stoolsYour prescriberTodayMedication Guide [1]
Nausea that bothers you or keeps returning after each dose increaseYour prescriber at the next appointmentAt your next appointmentMedication Guide [1]

Questions

Is nausea more common on Wegovy® 7.2 mg than on 2.4 mg?

In the two 72-week trials that tested both strengths, 39% on 7.2 mg and 35% on 2.4 mg reported nausea, compared with 13% on placebo. [1] Those figures describe that pool only.

Do teenagers on Wegovy® get nausea as often as adults?

In the adolescent trial, 42% on the injection reported nausea against 18% on placebo, close to the 44% in the adult 2.4 mg pool. Vomiting was more frequent among teenagers (36%). [1] The Canadian monograph adds that adolescents may stay on a lower dose if 2.4 mg is not tolerated, a call for their prescriber. [3]

How long does Wegovy® nausea usually last?

In the STEP 1–4 trials, the median nausea episode lasted 8 days. [2] The label does not promise a duration, and the Medication Guide asks you to report side effects that trouble you or persist. [1]

Does nausea mean Wegovy® is working better?

Not according to a pooled analysis of STEP 1–3: average weight loss was similar in people with and without digestive side effects, and less than one percentage point of the difference from placebo was linked to them. [5]

My nausea came back after I missed two weekly doses. Why?

The label says that after two or more missed doses in a row, the dose should be built up again from a lower step to reduce stomach reactions, and the Medication Guide asks you to contact your provider about how to restart. [1]

Can I take an anti-nausea medicine with Wegovy®?

The Wegovy® label does not cover this. It asks you to tell your provider about all medicines and supplements, including over-the-counter products, because Wegovy® slows stomach emptying and can affect some of them. [1] Ask your pharmacist or prescriber first.

Sources

Sources checked on

  1. WEGOVY® (semaglutide) injection and tablets Prescribing Information and Medication Guide, Novo Nordisk Revised 06/2026. Sections 2.2, 2.4, 5.2, 5.6, 6.1 (Tables 3–5), 7.2, 12.2, 17 and Medication Guide.
  2. Wegovy: EPAR – Product Information (SmPC and package leaflet), European Medicines Agency Sections 4.5, 4.8 (Table 3 and gastrointestinal adverse reactions) and 5.1.
  3. WEGOVY® (semaglutide injection) Product Monograph, Novo Nordisk Canada Inc. Date of authorization 10 December 2025. Sections 8.1, 8.2 (Table 4) and Patient Medication Information.
  4. Wegovy® Side Effects, Novo Nordisk (wegovy.com) Manufacturer’s US patient page; “Tips for managing nausea”. Checked 20-10-2026.
  5. Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105 Pooled analysis of STEP 1–4 randomised trials; abstract. Manufacturer-funded.
  6. Shu Y, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179 FAERS disproportionality analysis; abstract. Voluntary reports cannot show cause or rate.
  7. Hiramoto B, et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis. Am J Gastroenterol. 2024;119(6):1126–1140 Meta-analysis of 15 studies across GLP-1 medicines; abstract.
  8. Nausea and vomiting – adults, MedlinePlus Medical Encyclopedia Causes, home care and when to contact a professional.
  9. Dehydration, MedlinePlus Medical Encyclopedia Signs of mild, moderate and severe dehydration.

Set up your lab tonight.

It takes a few minutes. Pep will be waiting.